GlassScriptPhysician profile
Paul Macdonald
NPI 1518929249
$650.14
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2021: $135 · 2022: $48.65 · 2023: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $103.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $134.99 | 2021 | |
| Argenx US, INC. | $103.72 | 2023 | Vyvgart |
| Medtronic Vascular, INC. | $65.68 | 2019 | |
| Amgen INC. | $52.49 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.78 | 2019 | |
| Ucb, INC. | $26.89 | 2019 | |
| Neurocrine Biosciences, INC. | $20.14 | 2019 | |
| Amneal Pharmaceuticals LLC | $19.22 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.83 | 2019 | |
| Biogen, INC. | $16.73 | 2019 | |
| Acorda Therapeutics, INC | $16.63 | 2019 | |
| Lilly USA, LLC | $15.01 | 2019 | |
| Genzyme Corporation | $14.69 | 2019 | |
| Grifols USA, LLC | $14.48 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $13.61 | 2019 | |
| Livanova USA, INC. | $13.34 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.18 | 2019 | |
| Assertio Therapeutics, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.